- Conditions
- Neoplasm Metastasis
- Interventions
- Docetaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine, Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2027
- U.S. locations
- 49
- States / cities
- Duarte, California • Redondo Beach, California • San Francisco, California + 42 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 13,800
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Nivolumab, Elotuzumab, Pomalidomide, Dexamethasone
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 65 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- LY3209590, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 33
- States / cities
- Concord, California • Fresno, California • Ventura, California + 29 more
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
- Conditions
- Iron Deficiency Anemia
- Interventions
- Ferumoxytol, Placebo
- Drug · Other
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 812 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 137
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 105 more
- Conditions
- Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 53
- States / cities
- Bakersfield, California • Encino, California • Glendale, California + 49 more
- Conditions
- Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
- Interventions
- Irinotecan, Ramucirumab, Blood for angiome profiling, Blood for cfDNA
- Drug · Genetic
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 4
- States / cities
- Miami, Florida • Tampa, Florida • St Louis, Missouri + 1 more
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- ABT-874
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 80 more
- Conditions
- Cancer, General Research Use
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 200,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2070
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Atlanta, Georgia • Honolulu, Hawaii + 7 more
- Conditions
- Breast Cancer
- Interventions
- Sapanisertib, Fulvestrant, Exemestane
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 30
- States / cities
- Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- Comparator administered in parent trial, Technosphere Insulin Inhalation Powder
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Fresno, California • Long Beach, California • Atlanta, Georgia + 10 more
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases, Cognition
- Interventions
- EVP-6124, Placebo
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Chino, California • Costa Mesa, California + 21 more
- Conditions
- Breast Cancer
- Interventions
- Cyclophosphamide, Docetaxel, Doxorubicin, Tamoxifen
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- Female only
- Enrollment
- 2,411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2010
- U.S. locations
- 134
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 115 more
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Up to 1 Year
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 8
- States / cities
- Jonesboro, Arkansas • Tampa, Florida • Idaho Falls, Idaho + 5 more
- Conditions
- Anesthesia
- Interventions
- Urine cocaine negative, Urine cocaine positive
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Glaucoma
- Interventions
- Model iS3 three-stent trabecular micro-bypass system
- Device
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hemophilia
- Interventions
- Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
- Biological
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 27
- States / cities
- San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more
- Conditions
- Fabry Disease
- Interventions
- Lucerastat, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Irvine, California • Oakland, California + 14 more
- Conditions
- Chickenpox
- Interventions
- Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more
- Conditions
- Lung Carcinoma
- Interventions
- Varenicline, Placebo, Tobacco Cessation Counseling
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 374
- States / cities
- Fairbanks, Alaska • Kingman, Arizona • Jonesboro, Arkansas + 236 more
- Conditions
- Apparent Mineralocorticoid Excess Syndrome
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- New York, New York • Dallas, Texas
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Etoposide, Ifosfamide, Intensity-Modulated Radiation Therapy
- Radiation · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Downey, California + 115 more
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
- Interventions
- Dupilumab SAR231893, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Roseville, California • Stockton, California • Denver, Colorado + 7 more
- Conditions
- Renal Failure
- Interventions
- LCP-Tacro tablets, Prograf
- Drug
- Lead sponsor
- Asahi Kasei Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 13
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 10 more